Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06839469 · ClinicalTrials.gov registry record
Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
A clinical trial of Spinal Muscular Atrophy Type 3 and Duchenne Muscular Dystrophy (DMD), sponsored by Columbia University.
- Recruiting
- Registry status
- 106
- Enrollment target
- 3
- Study locations
NCT06839469 is a study of Spinal Muscular Atrophy Type 3 and Duchenne Muscular Dystrophy (DMD) that is actively recruiting participants, run by Columbia University. The registered enrollment target is 106 participants, above the 83-participant average among 9 other Spinal Muscular Atrophy Type 3 trials with a reported enrollment target (28% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT06839469, a study of Spinal Muscular Atrophy Type 3 and Duchenne Muscular Dystrophy (DMD), is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- 106 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research is (1) to identify disease specific walking-related digital biomarkers of disease severity, and (2) monitor longitudinal changes in natural environments, for extended periods of time, in DMD and SMA.
Conditions Studied
Study Locations (3)
California
- Stanford University - Palo Alto
Massachusetts
- Boston Children's Hospital - Boston
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2028-04-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06839469
The ClinicalTrials.gov registry entry for NCT06839469 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 83-participant average among 9 other Spinal Muscular Atrophy Type 3 trials with a reported enrollment target (28% higher). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Spinal Muscular Atrophy Type 3 appearing as the primary indexed condition, and to 0 interventions.
NCT06839469 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT06839469 about?
NCT06839469 is a clinical study titled "Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders". The purpose of this research is (1) to identify disease specific walking-related digital biomarkers of disease severity, and (2) monitor longitudinal changes in natural environments, for extended periods of time, in DMD and SMA.
What is the current status of trial NCT06839469?
This trial is currently recruiting. The enrollment target is 106 participants. The study started on 2024-05-01. Estimated completion is 2028-04-01.
What conditions does trial NCT06839469 study?
This clinical trial studies the following conditions: Spinal Muscular Atrophy Type 3, Duchenne Muscular Dystrophy (DMD).
Who is sponsoring clinical trial NCT06839469?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06839469 being conducted?
This trial has 3 study locations across California, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Muscular Atrophy Type 3
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gait and Bone Health in SMA
RECRUITING
-
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
RECRUITING · Phase 2
-
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb
ACTIVE NOT RECRUITING · NA
-
Spinraza in Adult Spinal Muscular Atrophy
ACTIVE NOT RECRUITING
-
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
ACTIVE NOT RECRUITING · Phase 3
-
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
COMPLETED · Phase 2
Explore more on PlainTrial
Spinal Muscular Atrophy Type 3
All registered trials for this condition
Duchenne Muscular Dystrophy (DMD)
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.